Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response | Zendy

Norihiro Furusyo | Zendy; Masayuki Murata | Zendy; Eiichi Ogawa | Zendy; Kazuhiro Toyoda | Zendy; T. Ihara | Zendy; Hiroaki Ikezaki | Zendy; T. Hayashi | Zendy; Toshiki Koga | Zendy; Mosaburo Kainuma | Zendy; J. Hayashi | Zendy

Open Access

Ribavirin concentration in the later stages of 48 week pegylated interferon- 2b plus ribavirin therapy for chronic hepatitis C is useful for predicting virological response

Author(s) -

Norihiro Furusyo,

Masayuki Murata,

Eiichi Ogawa,

Kazuhiro Toyoda,

T. Ihara,

Hiroaki Ikezaki,

T. Hayashi,

Toshiki Koga,

Mosaburo Kainuma,

J. Hayashi

Publication year - 2011

Publication title -

journal of antimicrobial chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.124

H-Index - 194

eISSN - 1460-2091

pISSN - 0305-7453

DOI - 10.1093/jac/dkr034

Subject(s) - ribavirin , medicine , pegylated interferon , gastroenterology , hepatitis c virus , hepatitis c , alpha interferon , chronic hepatitis , interferon , immunology , virus

The current standard of care for chronic hepatitis C patients is a pegylated interferon-α plus ribavirin combination treatment. This study was carried out to determine the relationship between ribavirin concentration in the later stages of treatment and virological relapse.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research